GOG-3011 (0403) FORWARD1: A Randomized, Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Adults with Folate Receptor a-positive Advanced

Grants and Contracts Details


ABSTRACT COPIED FROM CLINICALTRIALS.GOV This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.
Effective start/end date6/8/173/14/19


  • Gynecological Oncology Group Foundation Incorporated: $20,548.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.